BBOT Stock Forecast & Price Target

BridgeBio Oncology is attractive because its three-program RAS pipeline targets some of the most validated and commercially meaningful oncogenic drivers in cancer, with BBO-8520, BBO-10203, and BBO-11818 designed for synergistic monotherapy and combination use across KRAS-mutant solid tumors. The lead asset has already shown encouraging clinical activity, including a 75% ORR at 500 mg QD and 53% ORR across dose levels in September '26, while BBO-10203 has shown no hyperglycemia to date and BBO-11818 may offer tolerability and sequencing advantages. Financially, the company ended 3Q26 with $315.3M in cash and investments, expected to fund operations into 2029, supporting multiple upcoming readouts in 4Q26 and mid-'27 that could further de-risk a pipeline with about $7.5bn in modeled worldwide peak sales potential.

BridgeBio Oncology is facing a negative fundamental setup because its strategic streamlining pushes meaningful data readouts into mid-’27, while BBO-11818 and BBO-10203 combination results were pushed out from 2H26 and the company also removed BBO-10203 revenues in mBC from its model. Although BBO-8520 showed 75% ORR in 17 experienced NSCLC patients and 63% ORR in 41 naïve patients, the shift from 1L to 2L+ NSCLC materially shrinks the commercial opportunity and has already pressured shares as investors strip legacy indications from models. With all three candidates still in Ph1, a crowded KRAS/RAS landscape, and ongoing regulatory and reimbursement risk, the company’s valuation remains highly dependent on early clinical success that is far from assured.